Amit Kohli has been at the helm of Antev for less than two months, but the new chief executive has already devised a strategy for the clinical-stage biopharmaceutical company to establish its product teverelix TFA, as the gold standard treatment in its indications.
Those indications include prostate cancer, benign prostatic hyperplasia, acute urinary retention for men and in women endometriosis and uterine fibroids. Kohli says regulators at both the FDA and EMA have given the company ' a clear pathway to regulatory approval.' He describes those discussions about a single arm non-controlled trial as 'amazing.'
Antev is seeking funding which Kohli says includes an IPO possibly at Nasdaq Europe or US in parallel with trade deals.